Analysed WUXI BIOLOGICS CAYMAN - ADR (WXXWY:OTCMKTS) News Sources
WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic
13-01-2026
yahoo.com
Vertex Partners With WuXi To Broaden Autoimmune Pipeline Beyond Cystic Fibrosis
10-02-2026
yahoo.com
WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO
18-08-2026
yahoo.com
WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership
16-09-2026
yahoo.com
WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability
24-09-2026
yahoo.com
Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption
01-10-2026
yahoo.com
What is the current price of WUXI BIOLOGICS CAYMAN - ADR (WXXWY:OTCMKTS)?
The current price of WUXI BIOLOGICS CAYMAN - ADR (WXXWY:OTCMKTS) is $12.35.
WUXI BIOLOGICS CAYMAN - ADR (WXXWY:OTCMKTS) absolute price change since previous trading day?
The absolute price change of WUXI BIOLOGICS CAYMAN - ADR (WXXWY:OTCMKTS) since the previous trading day is $-0.71.
WUXI BIOLOGICS CAYMAN - ADR (WXXWY:OTCMKTS) percentage price change since previous trading day?
The percentage price change of WUXI BIOLOGICS CAYMAN - ADR (WXXWY:OTCMKTS) since the previous trading day is -5.4364%.
What is the most recent average sentiment score for WUXI BIOLOGICS CAYMAN - ADR (WXXWY:OTCMKTS)?
The most recent average sentiment score for WUXI BIOLOGICS CAYMAN - ADR (WXXWY:OTCMKTS) is 67 out of 100.
What is the most recent average sentiment for WUXI BIOLOGICS CAYMAN - ADR (WXXWY:OTCMKTS)?
The most recent sentiment for WUXI BIOLOGICS CAYMAN - ADR (WXXWY:OTCMKTS) is .
SEC-8K** Filing Available For WUXI BIOLOGICS CAYMAN - ADR (WXXWY:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.